CCA
VRTX icon

Cravens & Co Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cravens & Co Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
2,640
-564
-18% -$250K 0.88% 26
2026
Q1 		$1.43M Buy
3,204
+407
+15% +$190K 0.93% 25
2025
Q4 		$1.27M Sell
2,797
-480
-15% -$207K 0.83% 29
2025
Q3 		$1.28M Buy
3,277
+1,036
+46% +$433K 0.88% 26
2025
Q2 		$998K Buy
2,241
+63
+3% +$29K 0.74% 31
2025
Q1 		$1.06M Buy
2,178
+16
+0.7% +$7.46K 0.82% 27
2024
Q4 		$871K Sell
2,162
-46
-2% -$21.3K 0.66% 31
2024
Q3 		$1.03M Sell
2,208
-68
-3% -$32.7K 0.79% 26
2024
Q2 		$1.07M Buy
+2,276
New +$988K 0.79% 29

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cravens & Co Advisors's VRTX Position: Q2 2026 in Review

Cravens & Co Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, selling an estimated $250K and leaving 2,640 shares worth $1.31M. The position accounts for 0.88% of the portfolio, ranked #26.

Cravens & Co Advisors first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.43M in Q1 2026. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cravens & Co Advisors held 2,640 shares of Vertex Pharmaceuticals worth $1.31M as of Q2 2026.
  • Cravens & Co Advisors sold 564 Vertex Pharmaceuticals shares in Q2 2026, an estimated $250K.
  • Vertex Pharmaceuticals made up 0.88% of Cravens & Co Advisors's portfolio in Q2 2026, its #26 holding.
  • Cravens & Co Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Cravens & Co Advisors's Vertex Pharmaceuticals position peaked at $1.43M in Q1 2026.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.